Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC

Barclays PLC lifted its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 872.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,599 shares of the company’s stock after acquiring an additional 26,556 shares during the period. Barclays PLC owned about 0.11% of Alto Neuroscience worth $339,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ANRO. Bank of New York Mellon Corp acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at approximately $252,000. Rhumbline Advisers bought a new position in Alto Neuroscience during the 2nd quarter worth $113,000. TD Asset Management Inc bought a new position in Alto Neuroscience during the 2nd quarter worth $928,000. Bowie Capital Management LLC bought a new position in Alto Neuroscience during the 2nd quarter worth $462,000. Finally, Federated Hermes Inc. grew its stake in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after buying an additional 3,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

ANRO has been the subject of a number of recent research reports. Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus lowered their price objective on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock opened at $4.61 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The business has a fifty day simple moving average of $4.15 and a 200-day simple moving average of $9.20. Alto Neuroscience, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. Research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.